- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-3-mer
- Ligands
- 21 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA.2: 6 residues within 4Å:- Chain A: V.104, N.106, N.118, Y.135, L.137, D.290
1 PLIP interactions:1 interactions with chain A- Hydrophobic interactions: A:Y.135
NAG-NAG-BMA.11: 6 residues within 4Å:- Chain E: V.104, N.106, N.118, Y.135, L.137, D.290
1 PLIP interactions:1 interactions with chain E- Hydrophobic interactions: E:Y.135
NAG-NAG-BMA.20: 6 residues within 4Å:- Chain I: V.104, N.106, N.118, Y.135, L.137, D.290
1 PLIP interactions:1 interactions with chain I- Hydrophobic interactions: I:Y.135
- 3 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN.5: 13 residues within 4Å:- Chain A: S.179, P.182, V.224, L.231, N.232, C.347, G.348, Q.408, R.412, C.413, V.414, S.415
- Ligands: NAG-NAG.9
2 PLIP interactions:2 interactions with chain A- Hydrogen bonds: A:G.348, A:V.414
NAG-NAG-BMA-MAN-MAN-MAN.14: 13 residues within 4Å:- Chain E: S.179, P.182, V.224, L.231, N.232, C.347, G.348, Q.408, R.412, C.413, V.414, S.415
- Ligands: NAG-NAG.18
2 PLIP interactions:2 interactions with chain E- Hydrogen bonds: E:G.348, E:V.414
NAG-NAG-BMA-MAN-MAN-MAN.23: 13 residues within 4Å:- Chain I: S.179, P.182, V.224, L.231, N.232, C.347, G.348, Q.408, R.412, C.413, V.414, S.415
- Ligands: NAG-NAG.27
2 PLIP interactions:2 interactions with chain I- Hydrogen bonds: I:G.348, I:V.414
- 18 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.28: 5 residues within 4Å:- Chain A: Q.263, N.265, N.301, S.303, R.412
Ligand excluded by PLIPNAG.29: 5 residues within 4Å:- Chain A: N.332, S.333, T.341, N.355, S.357
Ligand excluded by PLIPNAG.30: 2 residues within 4Å:- Chain A: G.323, N.324
Ligand excluded by PLIPNAG.31: 3 residues within 4Å:- Chain A: K.304, A.305, N.308
Ligand excluded by PLIPNAG.32: 3 residues within 4Å:- Chain A: N.103, T.105, K.117
Ligand excluded by PLIPNAG.33: 3 residues within 4Å:- Chain A: V.144, R.162, N.167
Ligand excluded by PLIPNAG.34: 5 residues within 4Å:- Chain E: Q.263, N.265, N.301, S.303, R.412
Ligand excluded by PLIPNAG.35: 5 residues within 4Å:- Chain E: N.332, S.333, T.341, N.355, S.357
Ligand excluded by PLIPNAG.36: 2 residues within 4Å:- Chain E: G.323, N.324
Ligand excluded by PLIPNAG.37: 3 residues within 4Å:- Chain E: K.304, A.305, N.308
Ligand excluded by PLIPNAG.38: 3 residues within 4Å:- Chain E: N.103, T.105, K.117
Ligand excluded by PLIPNAG.39: 3 residues within 4Å:- Chain E: V.144, R.162, N.167
Ligand excluded by PLIPNAG.40: 5 residues within 4Å:- Chain I: Q.263, N.265, N.301, S.303, R.412
Ligand excluded by PLIPNAG.41: 5 residues within 4Å:- Chain I: N.332, S.333, T.341, N.355, S.357
Ligand excluded by PLIPNAG.42: 2 residues within 4Å:- Chain I: G.323, N.324
Ligand excluded by PLIPNAG.43: 3 residues within 4Å:- Chain I: K.304, A.305, N.308
Ligand excluded by PLIPNAG.44: 3 residues within 4Å:- Chain I: N.103, T.105, K.117
Ligand excluded by PLIPNAG.45: 3 residues within 4Å:- Chain I: V.144, R.162, N.167
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Cottrell, C.A. et al., Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. Plos Pathog. (2020)
- Release Date
- 2020-07-01
- Peptides
- Envelope glycoprotein gp120: AEI
Envelope glycoprotein gp41: BFJ
RM20J Heavy chain Fab: CGK
RM20J Kappa light chain: DHL - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AE
CI
DB
BF
EJ
FC
HG
GK
ID
LH
JL
K
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-3-mer
- Ligands
- 21 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 18 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Cottrell, C.A. et al., Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. Plos Pathog. (2020)
- Release Date
- 2020-07-01
- Peptides
- Envelope glycoprotein gp120: AEI
Envelope glycoprotein gp41: BFJ
RM20J Heavy chain Fab: CGK
RM20J Kappa light chain: DHL - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AE
CI
DB
BF
EJ
FC
HG
GK
ID
LH
JL
K